Utilizing the same drug in a dementia model based on STZ intracerebroventricular injection in rats, Nassar and colleagues reported that a five-week pramlintide administration (200 μg/kg) improved learning and memory while decreasing levels of p-tau and β-amyloid in the hippocampus of STZ-injected rats.67 The gene discussed is MAPT; the disease is dementia.